Published in Products

Bausch + Lomb launches enVista Aspire IOL in the US

This is editorially independent content
3 min read

Bausch + Lomb Corporation announced the U.S. launch of the latest enVista Aspire monofocal and toric intraocular lenses (IOLs) with intermediate optimized (IO) optics.

To get the latest details on the launch, Glance President Jackie Garlich, OD, FAAO, spoke with Anthony Wallace, B+L Surgical's vice president and general manager.

Let’s start with this enVista brand.

B+L’s enVista brand platform include both monofocal and toric hydrophobic acrylic IOLs that feature aberration-free optics and a distinctive lens design for stable performance (due to the use of the AccuSet Haptics, which can enable for extensive interaction with the capsular bag to aid in securing the lens position), predictability, and visual clarity.

See details on the enVista IOL family here, which include:

  • MX60E, MX60PL (monofocal)
  • MX60ET, MX60PT (toric)

Give me some details on their design.

The IOLs incorporate proprietary materials and technology such as:

  • TruSight Optic, a glistening-free material for increased scratch and abrasion resistance. Per B+L, the material is 25x harder than a standard hydrophobic acrylic lens.
    • To note, the enVista IOLs are the first and only single-piece, hydrophobic acrylic IOL available as glistening-free in the U.S.
  • SureEdge design, designed as a 360° posterior square edge with the potential to prevent posterior capsular opacification (vs round edge designs).

And the technology?

The company’s StableFlex technology is designed to provide controlled and efficient unfolding as well as to supply improved material properties for enhanced optic recovery.

Now talk about his news lens.

The enVista Aspire hydrophobic acrylic IOL (non-preloaded model EA) is indicated for primary implantation in the capsular bag of the eye of patients to visually correct aphakia after cataractous lens removal, according to B+L.

How does it work?

Per B+L, the IOL uses “an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter to slightly extend the depth of focus.

To note, though, this extension of the depth of focus has not been demonstrated in clinical trials.

Walker speaks about this below.

And its uniqueness?

The IOL features a low cylinder design, serves as an option for treatment of astigmatism during cataract surgery, and provides patients with a range of vision beyond one focal point.

Further, the enVista is currently the only toric IOL platform available that could treat less than one diopter (D) of astigmatism at the corneal plane.

See here for details on the target patient base for this.

So where can I find this?

No official word yet, but check in with your local B+L representative here.

And lastly … didn’t B+L recently announce a few product launches?


Last month, the company announced the U.S. launch of MIEBO (perfluorohexyloctane ophthalmic solution), the first and only DED treatment approved to directly target tear evaporation, as well as LUMIFY EYE ILLUMINATIONS (see here).

How would you rate the quality of this content?